PeptideDB

JNJ-16259685 409345-29-5

JNJ-16259685 409345-29-5

CAS No.: 409345-29-5

Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

JNJ16259685 (JNJ-16259685) is a novel, potent, selective and non-competitive antagonist of mGlu1 receptor with IC50 of 19 nM. JNJ16259685 did not alter immobility, but it did result in a notable decrease in offensive behaviors (attack and threat). In a concentration-dependent way, it prevents mGlu1 from being synaptically activated. Up to a dose of 30 mg/kg, JNJ16259685 had very little effect on hip flexion and posture. In rats, motor skill remained intact for well-learned tasks (up to 30 mg/kg), but in mice, it was impaired. The learning of a novel motor skill (rotarod) was severely hindered in both rats and mice rats (0.3 mg/kg).



Physicochemical Properties


Molecular Formula C20H23NO3
Molecular Weight 325.41
Exact Mass 325.168
Elemental Analysis C, 73.82; H, 7.12; N, 4.30; O, 14.75
CAS # 409345-29-5
Related CAS #
409345-29-5
PubChem CID 11313361
Appearance White to off-white solid powder
Density 1.21g/cm3
Boiling Point 502.5ºC at 760 mmHg
Flash Point 257.7ºC
Index of Refraction 1.604
LogP 3.947
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 4
Rotatable Bond Count 3
Heavy Atom Count 24
Complexity 446
Defined Atom Stereocenter Count 0
SMILES

O=C(C1=CC=C2N=C3C(CCCO3)=CC2=C1)[C@H]4CC[C@@H](OC)CC4

InChi Key QOTAQTRFJWLFCR-UHFFFAOYSA-N
InChi Code

InChI=1S/C20H23NO3/c1-23-17-7-4-13(5-8-17)19(22)14-6-9-18-16(11-14)12-15-3-2-10-24-20(15)21-18/h6,9,11-13,17H,2-5,7-8,10H2,1H3
Chemical Name

3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl-(4-methoxycyclohexyl)methanone
Synonyms

JNJ-16259685; JNJ 16259685; JNJ16259685
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets mGluR1 ( IC50 = 19 nM )
ln Vitro
JNJ16259685 potently and completely inhibits the increase in intracellular Ca2+ concentrations at the rat mGlu1a receptor that is induced by glutamate (30 μM) with an IC50 value of 3.24±1.00 nM. The IC50 values of BAY 36-7620 and CPCCOEt are 161±38 nM and 17.8±10.3 μM, respectively. JNJ16259685 is 1.21±0.53 nM (IC50 n=3) potent in inhibiting glutamate (30 μM)-induced Ca2+ mobilization at the human mGlu1a receptor. With an IC50 value of 1.31±0.39 μM (n=4), JNJ16259685 inhibits the rise in intracellular Ca2+ concentrations at the rat mGlu5a receptor that is induced by glutamate (3 μM). JNJ16259685 inhibits the activation of Ca2+ at the human mGlu5 receptor induced by glutamate (3 μM) with an IC50 of 28.3±11.7 μM (n=4). At none of the group I mGlu receptors, JNJ16259685 demonstrates agonist activity[3].
ln Vivo
JNJ-16259685 (0.125, 0.25, 0.5, 1, 2, 4 and 8 mg/kg, i.p) compares favorably to the vehicle group in terms of the amount of time spent on digging behaviors (0.25-8 mg/kg), threats (all doses), and attacks[1]. There is very little effect of JNJ16259685 (30 mg/kg) on locomotor activity. Rearing behavior, exploring a new environment, and pressing a lever to receive a food reward are all significantly reduced by JNJ16259685 (rat: 0.3 mg/kg; mouse: 1 mg/kg). JNJ16259685 (30 mg/kg) administered subcutaneously has no effect on mice's reflexive startle responses to loud auditory stimuli or foot shock[2]. In the rat cerebellum and thalamus, JNJ16259685 demonstrates strong potencies in occupying central mGlu1 receptors (ED50=0.040 and 0.014 mg/kg, respectively)[3].
Animal Protocol Mice: There are nine mouse groups in use. The animals are randomized into seven experimental groups (N=14–16 each) that receive injections of JNJ16259685 and two control groups (n=15 each) that receive only saline or saline (90%) plus DMSO (10%). In order to provide suitable injection doses, JNJ16259685 is diluted in saline (90%) plus DMSO (10%) and given in seven doses: 0.125, 0.25, 0.5, 1, 2, 4, and 8 mg/kg. The dosages are selected based on the results of recent behavioral research with this substance. Ten milliliters per kilogram of drug or vehicle are injected intraperitoneally.
Rats: The overt behavioral, neurological, and autonomic reactions to the drug challenge are measured using this procedure. In summary, rats are randomly assigned to four groups (n = 6), each of which is given a different dose of JNJ16259685 (0, 3, 10, or 30 mg/kg). The animals are evaluated and scored at 30, 60, 120, and 240 minutes after injection by a skilled observer who is blind to the drugs the animals are receiving. The animals are evaluated for gait, pupil size, body elevation, limb position, limb tone, and passivity. For every behavior, animals that seemed "normal" were given a score of 0, while animals that showed mild, moderate, or severe increases (+) or decreases (−) from normalcy were given scores of ±1, ±2, or ±3. Individual animals are deemed to be significantly affected on the measure if they score ±2 or higher. If three or more of the animals receive a score greater than ±2, the dose is deemed significant.
References

[1]. JNJ16259685, a selective mGlu1 antagonist, suppresses isolation-induced aggression in male mice. Eur J Pharmacol. 2008 May 31;586(1-3):217-20.

[2]. Characterization of the selective mGluR1 antagonist, JNJ16259685, in rodent models of movement and coordination. Pharmacol Biochem Behav. 2011 Apr;98(2):181-7.

[3]. JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology. 2004 Dec;47(7):961-72.

[4]. Potent and Specific Action of the mGlu1 Antagonists YM-298198 and JNJ16259685 on Synaptic Transmission in Rat Cerebellar Slices. Br J Pharmacol. 2007 Jul;151(6):870-6.

Additional Infomation 3,4-dihydro-2H-pyrano[2,3-b]quinolin-7-yl-(4-methoxycyclohexyl)methanone is an organonitrogen heterocyclic compound, an oxacycle and an organic heterotricyclic compound.

Solubility Data


Solubility (In Vitro)
DMSO: ≥100 mM (~307.3 mM)
Water: N/A
Ethanol: N/A
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.75 mg/mL (8.45 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.75 mg/mL (8.45 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.75 mg/mL (8.45 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.0730 mL 15.3652 mL 30.7305 mL
5 mM 0.6146 mL 3.0730 mL 6.1461 mL
10 mM 0.3073 mL 1.5365 mL 3.0730 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.